Carcinogen-induced Amplification of SV40 DNA Inserted at 9q12-21.1 Associated with Chromosome Breakage, Deletions, and Translocations in Human Uroepithelial Cell Transformation in Vitro
Overview
Oncology
Affiliations
The fate of integrated SV40 viral genome in SV40-immortalized human uroepithelial cells (SV-HUC) during multistep chemical transformation in vitro was studied. We previously reported that exposure of SV-HUC at passage (P) 15 to the chemical carcinogens 3-methylcholanthrene (MCA), 4-aminobiphenyl (ABP), or the N-hydroxy metabolites of ABP causes tumorigenic transformation and/or neoplastic progression. We report now that these same chemical carcinogens induce amplification of SV40 DNA in SV-HUC. We used fluorescence in situ hybridization (FISH) to show that this amplification occurs at the SV40 integration site, which was mapped near a common fragile site at 9q12-21.1 on the der(9)t(8;9) chromosome that is present in all SV-HUC at the earliest passage studied. Karyotypic analysis, along with FISH, also revealed that all carcinogen-induced tumors (T-SV-HUCs) had breaks at 9q12-21.1, deletions of 9q12-21.1-->pter, and new derivative chromosomes containing SV40 in the segment 9q12-21.1-->9q34::8q22-->8qter. Southern blot analysis, along with FISH, confirmed SV40 genome rearrangements in T-SV-HUCs. In contrast, no 9q12-21.1 breaks were observed in control SV-HUC. Thus, these results associate 9q12-21.1-->pter alterations with HUC tumorigenic transformation. In addition, these results indicate for the first time that (carcinogen-induced) amplification of chromosome-integrated viral genes may create sites that are prone to breakage, deletions, and translocations. These results suggest a new mechanism by which chemical carcinogens in synergy with a DNA tumor virus could initiate a cascade of events that contribute to the genomic instability associated with tumorigenesis.
Chromosomal Heteromorphisms and Cancer Susceptibility Revisited.
Liehr T Cells. 2022; 11(20).
PMID: 36291106 PMC: 9600968. DOI: 10.3390/cells11203239.
Yamada Y, Liao G, Tseng C, Tseng Y, Hsu W PLoS One. 2019; 14(12):e0226105.
PMID: 31805146 PMC: 6894772. DOI: 10.1371/journal.pone.0226105.
Al-Achkar W, Wafa A, Klein E, Aljapawe A Mol Cytogenet. 2011; 4:16.
PMID: 21851601 PMC: 3170627. DOI: 10.1186/1755-8166-4-16.
Crosby L, Moore T, George M, Yoon L, Easton M, Ni H Cancer Cell Int. 2010; 10:4.
PMID: 20178601 PMC: 2848030. DOI: 10.1186/1475-2867-10-4.
Kim S, Kim N, Dong B, Boren D, Lee S, Das Gupta J J Virol. 2008; 82(20):9964-77.
PMID: 18684813 PMC: 2566297. DOI: 10.1128/JVI.01299-08.